Laman UtamaKYNB • NASDAQ
add
Kyntra Bio Inc
Tutup sebelumnya
$7.10
Julat hari
$7.01 - $7.40
Julat tahun
$6.32 - $9.70
Permodalan pasaran
28.37J USD
Bilangan Purata
39.56K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | 1.28J | -59.27% |
Perbelanjaan pengendalian | 7.25J | -13.13% |
Pendapatan bersih | -14.22J | -179.08% |
Margin untung bersih | -1.11K | -294.14% |
Pendapatan bagi setiap syer | -3.51 | -75.50% |
EBITDA | -13.51J | 49.92% |
Kadar cukai berkesan | 0.00% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 88.98J | 76.26% |
Jumlah aset | 119.59J | -44.25% |
Jumlah liabiliti | 115.12J | -71.09% |
Jumlah ekuiti | 4.48J | — |
Syer tertunggak | 4.05J | — |
Harga kepada buku | -0.96 | — |
Pulangan pada aset | -26.34% | — |
Pulangan pada modal | -110.83% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -14.22J | -179.08% |
Tunai daripada operasi | -18.33J | 39.84% |
Tunai daripada pelaburan | -51.71J | -3,101.28% |
Tunai daripada pembiayaan | -14.00K | -380.00% |
Perubahan bersih dalam tunai | -70.10J | -143.20% |
Aliran tunai bebas | -10.14J | 90.52% |
Perihal
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Diasaskan
1 Jan 1993
Ibu pejabat
Tapak web
Pekerja
34
